CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Cytokinetics, Incorporated Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Bronstein, Gewirtz & Grossman LLC is pursuing a class action lawsuit against Cytokinetics, Incorporated for alleged securities law violations.Summary
Bronstein, Gewirtz & Grossman LLC has announced a class action lawsuit against Cytokinetics, Incorporated (NASDAQ: CYTK) and its officers. The lawsuit concerns alleged false and misleading statements made between December 27, 2023, and May 6, 2025, regarding the timeline for the New Drug Application (NDA) submission and approval process for aficamten. Specifically, the complaint alleges misrepresentation of the FDA approval timeline and failure to disclose risks, including the absence of a required Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process. Investors who experienced losses during the specified Class Period are encouraged to join the case and have until November 17, 2025, to request appointment as lead plaintiff. The firm represents investors on a contingency fee basis, meaning costs are only recovered if the case is successful.
(Source：FinancialContent)